Category: Diseases!
- APOE4 and myelin: Wnt signaling offers a research target in laboratory models ()
Published October 15, 2026. MIT researchers report a possible explanation for how the Alzheimer’s-associated APOE4 variant disrupts myelin, the fatty insulation around nerve fibers. Their study, published October 15 in Cell Stem Cell, links APOE4 to reduced Wnt signaling in oligodendrocytes, the cells that produce myelin. A genome-wide CRISPR screen in human cell cultures helped […]
- Recurring gliomas follow distinct genetic paths, longitudinal study finds ()
Published October 15, 2026. A Nature study published October 14 followed genetic changes in tumor samples from 183 patients with IDH-mutant glioma. The GLASS Consortium analysis compared samples collected at different surgeries to investigate how astrocytomas and oligodendrogliomas evolve as disease progresses. Recurrent oligodendrogliomas acquired new driver mutations, including changes involving PI3K and NOTCH1. Astrocytomas […]
- Zealand and Generate partner on AI-designed protein therapies for metabolic diseases ()
Published October 15, 2026. Zealand Pharma and Generate Biomedicines announced on October 13 a collaboration to develop multispecific protein therapeutics for obesity and other metabolic diseases. The approach combines generative AI with experimental testing to design proteins with selected biological functions. Generate will lead research through candidate selection; Zealand will take responsibility for subsequent clinical […]
- APN401 cell therapy: early safety and disease-stabilization findings reported ()
Published October 15, 2026. invIOs announced on October 15 that results from two Phase 1 studies of APN401 had been published in Molecular Therapy Oncology. The experimental cell therapy uses a patient’s own peripheral blood mononuclear cells, with siRNA temporarily reducing the immune checkpoint CBL-B. According to the company’s report, 17 patients with advanced solid […]
- Eikon submits EIK1006 application for prostate cancer clinical testing ()
Published October 15, 2026. Eikon Therapeutics announced on October 15 that it submitted an FDA Investigational New Drug application for EIK1006 in advanced metastatic prostate cancer. The company describes this experimental androgen receptor antagonist as structurally distinct from lutamide-class drugs and designed to target receptor variants associated with treatment resistance. Evidence limits: This is a […]
- MTX325 Parkinson’s Phase 1b Study Doses First Patient ()
Published October 15, 2026. Mission Therapeutics announced that the first participant with Parkinson’s disease has received MTX325 in its Phase 1b study. The experimental oral drug inhibits USP30 and is intended to improve mitochondrial quality control. The trial plans to assess biological mechanism, safety and tolerability in 36 people with mild to moderate Parkinson’s disease, […]
- DaltonTx Receives Gates Foundation Grant for AI Tuberculosis Drug Discovery ()
Published October 15, 2026. DaltonTx announced today that it has received a Gates Foundation grant to support AI-assisted tuberculosis drug discovery. The project will investigate hundreds of essential and vulnerable genes in Mycobacterium tuberculosis to identify potential drug targets and chemical starting points. The company plans to combine protein-structure prediction, machine learning and physics-based modelling. […]
- AstraZeneca and insitro Partner on AI Drug Discovery for Liver and Heart Diseases ()
Published October 15, 2026. AstraZeneca announced an AI drug-discovery partnership with insitro today, targeting metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. insitro’s Virtual Human platform will combine human and cellular data to investigate disease drivers and develop candidate medicines. AstraZeneca will advance selected programmes. The agreement includes US$40 million upfront, up to approximately US$1.46 billion in […]
- Experimental myosin inhibitor restores capillary flow in animal models of heart and kidney injury ()
Published October 15, 2026. A Nature study published on October 14 reports an experimental compound, R(+)2501, that restored blood flow through capillaries in animal models of heart attack and acute kidney injury. The research addresses capillary no-reflow: small vessels can remain obstructed even after circulation through a larger artery has been restored. The compound inhibits […]
- Genezen and Galibra prepare GAL005 gene therapy manufacturing for planned human testing ()
Published October 14, 2026. Genezen and Galibra Neuroscience announced a manufacturing partnership for GAL005, an investigational AAV gene therapy targeting succinic semialdehyde dehydrogenase (SSADH) deficiency. The inherited disorder affects GABA metabolism and is associated with mutations in ALDH5A1. Genezen will manufacture material for toxicology and biodistribution studies needed to support an investigational new drug application, […]